TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05288452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching
Description: The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Health Coaching
Description: The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Health Coaching
Description: The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Health Coaching
Description: The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Box Delivery
Description: The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food Box Delivery
Description: The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food Box Delivery
Description: The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food Box Delivery
Description: The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring (RPM)
Description: The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
Study: NCT05495412

Intervention type: OTHER
Group type: OTHER
Intervention: Rebound therapy
Description: Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
Study: NCT05288452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Monitoring (RPM)
Description: The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Monitoring (RPM)
Description: The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Monitoring (RPM)
Description: The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.
Study: NCT06721117

Intervention type: OTHER
Intervention: Pain threshold assessment
Description: Pain sensitivity to pressure will be assessed with a pain measuring device called an algometer. The Baseline Dolorimeter brand algometer will be used in the assessment. 3 measurements will be taken from the midpoint of the upper trapezius muscle and C7 points between the lateral edge of the acromion and C7. The areas will be marked before the measurement. The algometer will be placed perpendicular to these points. The patients will be asked to report the moment they first felt the pain and 30 seconds of rest will be given between the measurements. The value on the display will be read and the pain threshold will be recorded in pounds (1kg=2.2 pounds).

Intervention type: OTHER
Intervention: Anxiety level assessment
Description: The anxiety level will be determined with the Beck Anxiety Inventory. The Beck Anxiety Inventory is a scale developed by Aaron T. Beck (1988). This scale consists of 21 questions. For each item, the patient is asked to report how he/she has felt during the past week.~The items are scored as 0, 1, 2 or 3. The score range is between 0-63. For the total score, \< 21 is considered mild, 22-35 is considered moderate, and \> 36 is considered severe. The Turkish validity study of the Beck anxiety scale was conducted by Ulusoy et al (1996).
Study: NCT06720025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL-0951 tablets
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO injection
Description: Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT06721390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano Improvisation
Description: Piano Improvisation taught by a professional instructor for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Music Listening facilitated by a professional instructor for 12 weeks.
Study: NCT05288452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Class
Description: The diabetes education class will be administered by a certified diabetes educator.
Study: NCT06317870

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Spinal anesthesia will be performed as follows: patient will be placed in the lateral decubitus position on the non-operative side. Using sterile gloves red chlorhexidine 2% alcohol solution will be used for skin disinfection. The site will be secured with a sterile drape, and the L4-L5 lumbar space identified. After subcutaneous local infiltration with 1% lidocaine, a 25G Whitacre pencil point spinal needle will be used to access the intrathecal space with free flow of cerebrospinal fluid as confirmation. A mixture of 12.5 mg of isobaric bupivacaine and 100 mcg of morphine will be administered intrathecally.~After the spinal anesthesia, the intrathecal morphine (ITM) group will receive a sham PENG block with the block needle inserted subcutaneously, the anesthesiologist using the same verbal block confirmation commands aspirate, inject but the needle withdrawn without injection. This will create the appearance of an identical cutaneous injection site to ensure patient blinding.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (PENG)
Description: Spinal anesthesia with intrathecal injection of 12.5 mg of isobaric bupivacaine will be performed, followed by a PENG block.~After skin disinfection, a low frequency curvilinear ultrasound probe (2-5 MHz 8870, BK ultrasound, Peabody Massachussets, US) with a sterile covering will be used to identify the anterior inferior iliac spine, the pubic eminence and the psoas tendon with its fascial plane. A 22 gauge 10cm block needle (Sonoplex® Pajunk, Geisingen, DE), will be used to enter the fascial plane and 20ml of 0.75% Ropivacain (Fresenius Kabi, Krienz CH) will be injected.
Study: NCT05591404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: Participants randomized to the TSST arm will experience the Trier Social Stress Test.
Study: NCT06346197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
Study: NCT05524402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOR-C 1
Description: TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
Study: NCT06346197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox Protocol
Description: oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
Study: NCT05524402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TOR-C 2
Description: TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
Study: NCT05435027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R912, samRNA-Spikebeta-TCE11
Description: IM injection of GRT-R912. Doses will be decided after safety review of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R912, samRNA-Spikebeta-TCE11
Description: IM injection of GRT-R912. Doses will be decided after safety review of Part A.
Study: NCT05963854

Intervention type: OTHER
Intervention: Survey Curbside
Description: Observational. Waste will be collected on specific days for 2 consecutive weeks and surveys will be completed to coincide with the waste collections.
Study: NCT04822246

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control: Hand instrumentation for caries excavation
Description: An enamel hatchet will be used to create access to the carious lesion and then removal of soft carious tissue will be undertaken with excavators. Excavation will be stopped when some resistance to excavation will be felt and the cavity will be then conditioned with polyacrylic acid for 20 s, washed and dried with cotton pellets. A high-viscosity glass-ionomer cement will be used to restore the cavity. Moisture control will be achieved with the use of cotton wool rolls. A chair-side assistant will hand-mix the glass-ionomer according to manufacturers' instructions and it will be placed in the cavity using the press-finger technique whenever the type of cavity allows it. In the case of root restorations, a glove coated with petroleum jelly will be used similarly to the press-finger technique to better condense the material into the cavity. Excess material will be removed; the restoration will be coated with petroleum jelly. No local anaesthetic will be used to provide ART treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention 1: EMS Airflow device for caries excavation
Description: An enamel hatchet will first be used to gain access into the cavity. Then the powder-water prophylaxis device will be used for the removal of soft carious tissue with the sodium bicarbonate powder-water jet. Excavation will be stopped when the colour of the lesion begins to darken and all the soft deposits are evacuated. The excavation will be done intermittently allowing sufficient time to check with hand instrument the surface hardness of the lesion. If the lesion is still soft excavation will be continued until the surface is hard suitable for restoring. The cavity will be then rinsed with copious water spray to evacuate all the powder-water material. The restoration procedure with a glass-ionomer cement will be done following the same procedures as in the control group.
Study: NCT06701786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compressive Sutures (CSs) group
Description: The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1mm, 2 horizontal incisions of approximately 3mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed . The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones. Three compressive sutures will be placed on the repositioned flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without Compressive Sutures (WCSs) group
Description: The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; than then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
Study: NCT06702137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (active)
Description: This study aims to evaluate the effects of the EXOPULSE Mollii suit, a non-invasive assistive device that delivers transcutaneous electrostimulation. The suit includes a CE-labeled class IIa control unit and class I body garments. Equipped with 58 electrodes, the full-body suit stimulates various muscle groups to reduce spasticity by activating antagonistic muscles through reciprocal inhibition, rather than causing muscle contractions. Designed to relax spastic muscles, improve range of motion, prevent atrophy, enhance circulation, and provide pain relief, the device is easy to use, requiring only one hour of daily wear, with effects lasting over 24 hours.~Current treatments for spasticity, such as botulinum toxin and oral medications, have limitations like side effects and minimal mobility improvement. The EXOPULSE Mollii suit offers an innovative alternative, with early studies indicating positive impacts on mobility and motor function.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study: NCT06632990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-984923
Description: oral capsules once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-984923
Description: oral capsules once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-984923
Description: oral capsules once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam, oral, 2mg administered before study drug and after study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine, oral, 100mg administered before study drug and after study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Description: dextromethorphan, oral, 30mg administered before study drug and after study drug
Study: NCT06700642

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: In this study, 3 intervention tools were developed by the researchers. The first of these, 'Rational Drug Use Trainer Guide', was used for trainer training and standardisation of the education given to patients. The sample rational drug use presentations prepared by the Ministry of Health, Turkiye Medicines and Medical Devices Agency, Department of Rational Drug Use were combined in terms of content, enriched with information obtained from the literature and developed for the use of family physicians working in primary health care institutions in their clinical practices.~'Rational Drug Use Individual Education Presentation' was prepared by the researchers in line with the 'Rational Drug Use Trainer Guide'. It has been prepared in a format suitable for individual education presentation with the most concise and understandable content suitable for use during primary healthcare service delivery.~'Rational Drug Use Patient Brochure' was prepared by the researchers in a similar content.
Study: NCT06699771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCC2005
Description: CAR-NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study: NCT04541758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: surgical treatment and Conservative treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: Conservative treatment
Study: NCT05435027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R914, samRNA-Spikebeta-TCE9
Description: Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R914, samRNA-Spikebeta-TCE9
Description: Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R918, samRNA-SpikeOmicron-N-TCE11
Description: IM injection of GRT-R918. Doses will be decided after safety review of Part A.
Study: NCT06702501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PeriCut Catheter System performs minimally invasive pericardiotomy
Description: The PeriCut Catheter System will incise the pericardium to reduce filling pressures of the heart.
Study: NCT06703710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JW2286
Description: a single administration of JW2286 per dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of JW2286
Description: a single administration of Placebo of JW2286 per dose
Study: NCT06703437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydrated alcohol
Description: Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: By periprostatic injection, 2mL
Study: NCT04541758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: Conservative treatment